Search

Your search keyword '"Maki, R.G."' showing total 107 results
Start Over Author "Maki, R.G."
107 results on '"Maki, R.G."'

1. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Author

Demetri, G.D., Antonescu, C.R., Bjerkehagen, B., Bovée, J.V.M.G., Boye, K., Chacón, M., Dei Tos, A.P., Desai, J., Fletcher, J.A., Gelderblom, H., George, S., Gronchi, A., Haas, R.L., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Judson, I., Kang, Y.-K., Kawai, A., Lazar, A.J., Le Cesne, A., Maestro, R., Maki, R.G., Martín, J., Patel, S., Penault-Llorca, F., Premanand Raut, C., Rutkowski, P., Safwat, A., Sbaraglia, M., Schaefer, I.-M., Shen, L., Serrano, C., Schöffski, P., Stacchiotti, S., Sundby Hall, K., Tap, W.D., Thomas, D.M., Trent, J., Valverde, C., van der Graaf, W.T.A., von Mehren, M., Wagner, A., Wardelmann, E., Naito, Y., Zalcberg, J., and Blay, J.-Y.

Published
2020
Full Text
View/download PDF

2. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study

Author

Fiocco, M., Dijkstra, P.D.S., Van der Wal, R.J.P., Daolio, P.A., Picci, P., Gronchi, A., Ferrari, S., Özger, H., Maki, R.G., Schreuder, H.W.B., Van der Geest, I.C.M., Bramer, J.A.M., Mastboom, W.J.B., Boffano, M., Goldenitsch, E., Campanacci, D., Cuomo, P., Ferguson, P.C., Griffin, A.M., Sun, Y., Schubert, T., Patel, K., Aranguren, M.S.J., Blancheton, A., Gouin, F., Dürr, H.R., Capellen, C.F., Schwab, J., Iwata, S., Vyrva, O., Weschenfelder, W., Wang, E.H.M., Wook Joo, M., Kang, Y.K., Chung, Y.G., Ebeid, W., Bruns, J., Ueda, T., Mastboom, Monique J L, Palmerini, Emanuela, Verspoor, Floortje G M, Rueten-Budde, Anja J, Stacchiotti, Silvia, Staals, Eric L, Schaap, Gerard R, Jutte, Paul C, Aston, Will, Gelderblom, Hans, Leithner, Andreas, Dammerer, Dietmar, Takeuchi, Akihiko, Thio, Quirina, Niu, Xiaohui, Wunder, Jay S, and van de Sande, Michiel A J

Published
2019
Full Text
View/download PDF

3. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group

Author

Giani, C., Denu, R.A., Ljevar, S., Gronchi, A., Napolitano, A., Rosenbaum, E., Salawu, A., Bajpai, J., Connolly, E.A., Lee, A.T.J., Trent, J.C., Koseła-Paterczyk, H., Chia-Chen Li, Z., Ogura, K., Palmerini, E., Baldi, G.G., Brunello, A., Campos, F., Cicala, C.M., Maki, R.G., Wagner, A.J., Andelkovic, V., Loong, H.H., Wong, D.D., Jones, R.L., Tap, W.D., Taverna, S.M., Lazar, A.J., Demicco, E.G., Hong, A., Bovee, J.V.M.G., Dei Tos, A.P., Fletcher, C.D.M., Baumhoer, D., Sbaraglia, M., Schaefer, I.M., Miceli, R., and Stacchiotti, S.

Published
2024
Full Text
View/download PDF

6. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10

Author

Blay, J.Y., Palmerini, E., Bollard, J., Aguiar, S., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., Chs, Caro-Sánchez, Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, 5th, Chacón, M., Clara-Altamirano, M.A., Collini, P., Correa Genoroso, R., Costa, F.D., Cuellar, M., Dei Tos, A.P., Dominguez Malagon, H.R., Donati, D.M., Dufresne, A., Eriksson, M., Farias-Loza, M., Frezza, A.M., Frisoni, T., Garcia-Ortega, D.Y., Gerderblom, H., Gouin, F., Gómez-Mateo, M.C., Gronchi, A., Haro, J., Hindi, N., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes, A., Lopes David, B.B., Lopez-Pousa, A., Lutter, G., Maki, R.G., Martinez-Said, H., Martinez-Tlahuel, J.L., Mello, C.A., Morales Pérez, J.M., Moura, D.S., Nakagawa, S.A., Nascimento, A.G., Ortiz-Cruz, E.J., Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Santos, T.G., Scotlandi, K., Mlg, Silva, Soulé, T., Stacchiotti, S., Valverde, C.M., Waisberg, F., Zamora Estrada, E., and Martin-Broto, J.

Published
2022
Full Text
View/download PDF

18. A Phase 0 Master Protocol Utilizing a Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Drug Combinations in Patients with Solid Tumors

Author

Ow, T.J., primary, Mehta, V., additional, Gersten, A.J., additional, Newman, J.G., additional, Maki, R.G., additional, Gundle, K.R., additional, Clayburgh, D.R., additional, Li, R.J., additional, Porosnicu, M., additional, Nathan, C.A.O., additional, Hatton, B.A., additional, Sottero, K.H.W., additional, Kung, G., additional, Grenley, M.O., additional, Anderson, K., additional, and Klinghoffer, R.A., additional

Published
2022
Full Text
View/download PDF

21. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

Author

Frezza, A.M., Assi, T., Vullo, S. Lo, Ben-Ami, E., Dufresne, A., Yonemori, K., Noguchi, E., Siontis, B., Ferraro, R., Teterycz, P., Duffaud, F., Ravi, V., Vincenzi, B., Gelderblom, H., Pantaleo, M.A., Baldi, G.G., Desar, I.M., Fedenko, A., Maki, R.G., Jones, R.L., Benjamin, R.S., Blay, J.Y., Kawai, A., Gounder, M., Gronchi, A., Cesne, A. Le, Mir, O., Czarnecka, A.M., Schuetze, S., Wagner, A.J., Adam, J., Barisella, M., Sbaraglia, M., Hornick, J.L., Meurgey, A., Mariani, L., Casali, P.G., Thornton, K., Stacchiotti, S., Frezza, A.M., Assi, T., Vullo, S. Lo, Ben-Ami, E., Dufresne, A., Yonemori, K., Noguchi, E., Siontis, B., Ferraro, R., Teterycz, P., Duffaud, F., Ravi, V., Vincenzi, B., Gelderblom, H., Pantaleo, M.A., Baldi, G.G., Desar, I.M., Fedenko, A., Maki, R.G., Jones, R.L., Benjamin, R.S., Blay, J.Y., Kawai, A., Gounder, M., Gronchi, A., Cesne, A. Le, Mir, O., Czarnecka, A.M., Schuetze, S., Wagner, A.J., Adam, J., Barisella, M., Sbaraglia, M., Hornick, J.L., Meurgey, A., Mariani, L., Casali, P.G., Thornton, K., and Stacchiotti, S.

Abstract

Contains fulltext : 220839.pdf (Publisher’s version ) (Closed access), BACKGROUND: Intimal sarcoma (InS) is an exceedingly rare neoplasm with an unfavorable prognosis, for which new potentially active treatments are under development. We report on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in patients with InS. METHODS: Seventeen sarcoma reference centers in Europe, the United States, and Japan contributed data to this retrospective analysis. Patients with MDM2-positive InS who were treated with anthracycline-based regimens, gemcitabine-based regimens, or pazopanib between October 2001 and January 2018 were selected. Local pathological review was performed to confirm diagnosis. Response was assessed by RECIST1.1. Recurrence-free survival (RFS), progression-free survival (PFS) and overall survival were computed by Kaplan-Meier method. RESULTS: Seventy-two patients were included (66 anthracycline-based regimens; 26 gemcitabine-based regimens; 12 pazopanib). In the anthracycline-based group, 24 (36%) patients were treated for localized disease, and 42 (64%) patients were treated for advanced disease. The real-world overall response rate (rwORR) was 38%. For patients with localized disease, the median RFS was 14.6 months. For patients with advanced disease, the median PFS was 7.7 months. No anthracycline-related cardiac toxicity was reported in patients with cardiac InS (n = 26). For gemcitabine and pazopanib, the rwORR was 8%, and the median PFS was 3.2 and 3.7 months, respectively. CONCLUSION: This retrospective series shows the activity of anthracycline-based regimens in InS. Of note, anthracyclines were used in patients with cardiac InS with no significant cardiac toxicity. The prognosis in patients with InS remains poor, and new active drugs and treatment strategies are needed.

Published
2020

23. Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints

Author

Mastboom, M.J.L., Staals, E.L., Verspoor, F.G.M., Rueten-Budde, A.J., Stacchiotti, S., Palmerini, E., Schaap, G.R., Jutte, P.C., Aston, W., Leithner, A., Dammerer, D., Takeuchi, A., Thio, Q., Niu, X., Wunder, J.S., Sande, M.A.J. van de, Fiocco, M., Dijkstra, P.D.S., Wal, R.J.P. van der, Daolio, P.A., Picci, P., Gronchi, A., Ferrari, S., Ozger, H., Maki, R.G., Schreuder, H.W.B., Geest, I.C.M. van der, Bramer, J.A.M., Mastboom, W.J.B., Boffano, M., Goldenitsch, E., Companacci, D., Cuomo, P., Ferguson, P.C., Griffin, A.M., Sun, Y., Schubert, T., Patel, K., Aranguren, M.S.J., Blancheton, A., Gouin, F., Durr, H.R., Capellen, C.F., Schwab, J., Iwata, S., Vyrva, O., Weschenfelder, W., Wang, E.H.M., Joo, M.W., Kang, Y.K., Chung, Y.G., Ebeid, W., Bruns, J., Ueda, T., and TGCT Study Grp

Subjects
Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]
Abstract

Contains fulltext : 208133.pdf (Publisher’s version ) (Closed access) Background: Localized-type tenosynovial giant cell tumor (TGCT) is a rare, neoplastic disease with only limited data supporting treatment protocols. We describe treatment protocols and evaluate their oncological outcome, complications, and functional results in a large multicenter cohort of patients. A secondary study aim was to identify factors associated with local recurrence after surgical treatment. Methods: Patients with histologically proven localized TGCT of a large joint were included if they had been treated between 1990 and 2017 in 1 of 31 tertiary sarcoma centers. Of 941 patients with localized TGCT, 62% were female. The median age at initial treatment was 39 years, and the median duration of follow-up was 34 months. Sixty-seven percent of the tumors affected the knee, and the primary treatment at the tertiary center was 1-stage open resection in 73% of the patients. Proposed factors for predicting a first local recurrence after treatment in the tertiary center were tested in a univariate analysis, and those that demonstrated significance were subsequently included in a multivariate analysis. Results: The localized TGCT recurred in 12% of all cases, with local-recurrence-free rates at 3, 5, and 10 years of 88%, 83%, and 79%, respectively. The strongest factor for predicting recurrent disease was a prior recurrence (p < 0.001). Surgical treatment decreased pain and swelling in 71% and 85% of the patients, respectively, and such treatment was associated with complications in 4% of the patients. Univariate and multivariate analyses of the patients who had not undergone therapy previously yielded positive associations between local recurrence and a tumor size of >= 5 cm versus

Published
2019

24. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study

Author

Mastboom, Monique J L, primary, Palmerini, Emanuela, additional, Verspoor, Floortje G M, additional, Rueten-Budde, Anja J, additional, Stacchiotti, Silvia, additional, Staals, Eric L, additional, Schaap, Gerard R, additional, Jutte, Paul C, additional, Aston, Will, additional, Gelderblom, Hans, additional, Leithner, Andreas, additional, Dammerer, Dietmar, additional, Takeuchi, Akihiko, additional, Thio, Quirina, additional, Niu, Xiaohui, additional, Wunder, Jay S, additional, van de Sande, Michiel A J, additional, Fiocco, M., additional, Dijkstra, P.D.S., additional, Van der Wal, R.J.P., additional, Daolio, P.A., additional, Picci, P., additional, Gronchi, A., additional, Ferrari, S., additional, Özger, H., additional, Maki, R.G., additional, Schreuder, H.W.B., additional, Van der Geest, I.C.M., additional, Bramer, J.A.M., additional, Mastboom, W.J.B., additional, Boffano, M., additional, Goldenitsch, E., additional, Campanacci, D., additional, Cuomo, P., additional, Ferguson, P.C., additional, Griffin, A.M., additional, Sun, Y., additional, Schubert, T., additional, Patel, K., additional, Aranguren, M.S.J., additional, Blancheton, A., additional, Gouin, F., additional, Dürr, H.R., additional, Capellen, C.F., additional, Schwab, J., additional, Iwata, S., additional, Vyrva, O., additional, Weschenfelder, W., additional, Wang, E.H.M., additional, Wook Joo, M., additional, Kang, Y.K., additional, Chung, Y.G., additional, Ebeid, W., additional, Bruns, J., additional, and Ueda, T., additional

Published
2019
Full Text
View/download PDF

25. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Author

Verspoor, F.G.M., Mastboom, M.J.L., Hannink, G.J., Maki, R.G., Wagner, A.J., Bompas, E., Graaf, W.T.A. van der, Gelderblom, H., Cassier, P.A., Verspoor, F.G.M., Mastboom, M.J.L., Hannink, G.J., Maki, R.G., Wagner, A.J., Bompas, E., Graaf, W.T.A. van der, Gelderblom, H., and Cassier, P.A.

Abstract

Contains fulltext : 209030.pdf (publisher's version ) (Open Access)

Published
2019

26. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Author

Jones, R.L. (Robin L.), Ratain, M.J. (Mark), O'Dwyer, P.J. (Peter J.), Siu, R.K. (Ronald), Jassem, J., Medioni, J. (Jacques), DeJonge, M.J.A. (Maja J.), Rudin, C.M. (Charles), Sawyer, M. (Michael), Khayat, D. (David), Awada, A. (Ahmad), de Vos-Geelen, J. (Judith), Evans, T.R.J. (Jeffry), Obel, J. (Jennifer), Brockstein, B. (Bruce), DeGreve, J. (Jacques), Baurain, J.F., Maki, R.G. (Robert G.), D'Adamo, D. (David), Dickson, M.A. (Mark A.), Undevia, S. (Samir), Geary, D. (David), Janisch, L. (Linda), Bedard, P.L. (Philippe L.), Abdul Razak, A.R. (Albiruni R.), Kristeleit, R.S. (R.), Vitfell-Rasmussen, J. (Joanna), Walters, I. (Ian), Kaye, S.B. (Stan B.), Schwartz, G. (Gary), Jones, R.L. (Robin L.), Ratain, M.J. (Mark), O'Dwyer, P.J. (Peter J.), Siu, R.K. (Ronald), Jassem, J., Medioni, J. (Jacques), DeJonge, M.J.A. (Maja J.), Rudin, C.M. (Charles), Sawyer, M. (Michael), Khayat, D. (David), Awada, A. (Ahmad), de Vos-Geelen, J. (Judith), Evans, T.R.J. (Jeffry), Obel, J. (Jennifer), Brockstein, B. (Bruce), DeGreve, J. (Jacques), Baurain, J.F., Maki, R.G. (Robert G.), D'Adamo, D. (David), Dickson, M.A. (Mark A.), Undevia, S. (Samir), Geary, D. (David), Janisch, L. (Linda), Bedard, P.L. (Philippe L.), Abdul Razak, A.R. (Albiruni R.), Kristeleit, R.S. (R.), Vitfell-Rasmussen, J. (Joanna), Walters, I. (Ian), Kaye, S.B. (Stan B.), and Schwartz, G. (Gary)

Abstract

Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]). Patients and methods: During a 12-week open-label lead-in period, patients received brivanib 800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee evaluated week 12 response to determine if enrolment in a tumour type would continue. The primary objective was progression-free survival (PFS) for brivanib versus placebo in patients with FGF2-positive tumours. Results: A total of 595 patients were treated, and stable disease was observed at the week 12 randomisation point in all tumour types. Closure decisions were made for breast cancer, pancreatic cancer, NSCLC, gastric cancer and TCC. Criteria for expansion were met for STS and ovarian cancer. In 53 randomised patients with STS and FGF2-positive tumours, the median PFS was 2.8 months for brivanib and 1.4 months for placebo (hazard ratio [HR]: 0.58, p = 0.08). For all randomised patients with sarcomas, the median PFS was 2.8 months (95% confidence interval [CI]: 1.4–4.0) for those treated with brivanib compared with 1.4 months (95% CI: 1.3–1.6) for placebo (HR = 0.64, 95% CI: 0.38–1.07; p = 0.09). In the 36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was 4.0 (95% CI: 2.6–4.2) months for brivanib and 2.0 months (95% CI: 1.2–2.7) for placebo (HR: 0.56, 95% CI: 0.26–1.22). For all randomised patients with ovarian cancer, the median PFS in those randomised to brivanib was 4.0 months (95% CI: 2.6–4.2) and was 2.0 months (95% CI: 1.2–2.7) in those randomised to placebo (H

Published
2019
Full Text
View/download PDF

28. Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study

Author

Hensley, M.L., primary, Patel, S.R., additional, Mehren, M.V., additional, Ganjoo, K., additional, Jones, R.L., additional, Staddon, A.P., additional, Rushing, D., additional, Milhem, M., additional, Monk, B.J., additional, Wang, G., additional, McCarthy, S., additional, Knoblauch, R., additional, Parekh, T., additional, Maki, R.G., additional, and Demetri, G.D., additional

Published
2016
Full Text
View/download PDF

29. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Author

Demetri, G.D., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., Mehren, M. von, Joensuu, H., Badalamenti, G., Blackstein, M., Cesne, A. le, Schoffski, P., Maki, R.G., Bauer, S., Nguyen, B.B., Xu, J., Nishida, T., Chung, J., Kappeler, C., Kuss, I., Laurent, D., Casali, P.G., Graaf, W.T.A. van der, Demetri, GD, Reichardt, P, Kang, YK, Blay, JY, Rutkowski, P, Gelderblom, H, Hohenberger, P, Leahy, M, von Mehren, M, Joensuu, H, Badalamenti, G, Blackstein, M, Le Cesne, A, Schöffski, P, Maki, RG, Bauer, S, Nguyen, BB, Xu, J, Nishida, T, Chung, J, Kappeler, C, Kuss, I, Laurent, D, Casali, PG, Demetri, Gd, Kang, Yk, Blay, Jy, Maki, Rg, Nguyen, Bb, Casali, Pg, Biasco, G, and study investigators, Grid

Subjects
Oncology, Male, Indoles, Pyridines, Settore MED/06 - Oncologia Medica, SU11248, Medizin, Piperazines, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Clinical endpoint, Sunitinib, Treatment Failure, regorafenib, gastrointestinal stromal tumours, imatinib and sunitinib, Gastrointestinal Neoplasms, education.field_of_study, GiST, KIT, Age-related aspects of cancer Quality of hospital and integrated care [ONCOL 2], General Medicine, Middle Aged, Survival Rate, Benzamides, Imatinib Mesylate, Female, ADJUVANT IMATINIB, TYROSINE KINASE INHIBITOR, Colorectal Neoplasms, Life Sciences & Biomedicine, medicine.drug, GROWTH-FACTOR, medicine.medical_specialty, Gastrointestinal Stromal Tumors, Population, MESYLATE, Antineoplastic Agents, IMATINIB, Article, MECHANISMS, Medicine, General & Internal, Double-Blind Method, Translational research [ONCOL 3], General & Internal Medicine, Regorafenib, Internal medicine, MANAGEMENT, medicine, Humans, Pyrroles, education, Protein Kinase Inhibitors, Aged, Science & Technology, GASTROINTESTINAL STROMAL TUMOURS, MUTATIONS, business.industry, Phenylurea Compounds, GIST, regorafenib, imatinib, sunitinib, phase III trial, Surgery, Clinical trial, Imatinib mesylate, Pyrimidines, chemistry, business, RESISTANCE
Abstract

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geographical region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 weeks of each 4 week cycle. The study sponsor, participants, and investigators were masked to treatment assignment. The primary endpoint was progression-free survival (PFS). At disease progression, patients assigned placebo could crossover to open-label regorafenib. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01271712. RESULTS: From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66). Data cutoff was Jan 26, 2012. Median PFS per independent blinded central review was 4.8 months (IQR 1.4-9.2) for regorafenib and 0.9 months (0.9-1.8) for placebo (hazard ratio [HR] 0.27, 95% CI 0.19-0.39; p

Published
2013

30. Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST

Author

Demetri, G.D., Jeffers, M., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., Mehren, M. von, Joensuu, H., Badalamenti, G., Blackstein, M., Cesne, A. le, Schoffski, P., Maki, R.G., Bauer, S., Nguyen, B.B., Xu, J.M., Nishida, T., Chung, J., Lathia, C.D., Kappeler, C., Kuss, I., Laurent, D., and Casali, P.G.

Subjects
Medizin
Published
2013

31. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

Author

Casali, P.G., primary, Reichardt, P., additional, Kang, Y., additional, Blay, J., additional, Joensuu, H., additional, Maki, R.G., additional, Rutkowski, P., additional, Hohenberger, P., additional, Gelderblom, H., additional, Leahy, M.G., additional, von Mehren, M., additional, Schoffski, P., additional, Blackstein, M.E., additional, Le Cesne, A., additional, Badalamenti, G., additional, Xu, J., additional, Nishida, T., additional, Laurent, D., additional, Kuss, I., additional, and Demetri, G.D., additional

Published
2015
Full Text
View/download PDF

32. 3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS)

Author

Patel, S., primary, Mehren, M. Von, additional, Reed, D., additional, Agulnik, M., additional, Kaiser, P., additional, Charlson, J., additional, Kraft, A., additional, Hamm, J., additional, Karnad, A., additional, Ryan, C., additional, Rushing, D., additional, Meyer, C., additional, Khokhar, N.Z., additional, McCarthy, S., additional, Park, Y.C., additional, Knoblauch, R.E., additional, Parekh, T.V., additional, Maki, R.G., additional, and Demetri, G.D., additional

Published
2015
Full Text
View/download PDF

34. 1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

Author

Von Mehren, M., primary, Demetri, G.D., additional, Schuetze, S.M., additional, Jones, R.L., additional, Milhem, M., additional, Elias, A., additional, Van Tine, B.A., additional, Hamm, J., additional, Khokhar, N.Z., additional, McCarthy, S., additional, Park, Y.C., additional, Knoblauch, R.E., additional, Parekh, T.V., additional, Maki, R.G., additional, and Patel, S.R., additional

Published
2015
Full Text
View/download PDF

35. 3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

Author

Demetri, G., primary, Patel, S.R., additional, Thomas, S., additional, Livingston, M., additional, Undevia, S.D., additional, Richardson, G., additional, Singh, A.S., additional, Seth, R., additional, Forscher, C., additional, Hinshaw, I., additional, Hussein, A., additional, D'Amato, G., additional, Chawla, S., additional, Khokhar, N.Z., additional, Park, Y.C., additional, Knoblauch, R.E., additional, Parekh, T.V., additional, Maki, R.G., additional, and Mehren, M. Von, additional

Published
2015
Full Text
View/download PDF

37. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

Author

Cassier, P.A., Gelderblom, H., Stacchiotti, S., Thomas, D, Maki, R.G., Kroep, J.R., Graaf, W.T.A. van der, Italiano, A., Seddon, B., Domont, J., Bompas, E., Wagner, A.J., Blay, J.Y., Cassier, P.A., Gelderblom, H., Stacchiotti, S., Thomas, D, Maki, R.G., Kroep, J.R., Graaf, W.T.A. van der, Italiano, A., Seddon, B., Domont, J., Bompas, E., Wagner, A.J., and Blay, J.Y.

Abstract

Item does not contain fulltext, BACKGROUND: Pigmented villonodular synovitis (PVNS) (also known as diffuse-type giant cell tumor) and tenosynovial giant cell tumors (TGCT) are rare, usually benign neoplasms that affect the synovium and tendon sheaths in young adults. These tumors are driven by the overexpression of colony stimulating factor-1 (CSF1). CSF1 is expressed by a minority of tumor cells, which, in turn attract non-neoplastic inflammatory cells that express CSF1 receptor (CSF1R) through a paracrine effect. METHODS: Imatinib mesylate (IM) blocks CSF1R, and previous case reports indicated that it also exerts antitumor activity in PVNS. The authors conducted a multi-institutional retrospective study to assess the activity of IM in patients with locally advanced/metastatic PVNS/TGCT. RESULTS: Twenty-nine patients from 12 institutions in Europe, Australia, and the United States were included. There were 13 men, the median age was 41 years, and the most common site of disease was the knee (n = 17; 59%). Two patients had metastatic disease to the lung and/or bone. Five of 27 evaluable patients had Response Evaluation in Solid Tumor (RECIST) responses (overall response rate, 19%; 1 complete response and 4 partial responses), and 20 of 27 patients (74%) had stable disease. Symptomatic improvement was noted in 16 of 22 patients (73%) who were assessable for symptoms. Despite a high rate of symptomatic improvement and a favorable safety profile, 6 patients discontinued because of toxicity, and 4 patients decided to discontinue IM for no clear medical reason. CONCLUSIONS: IM displayed interesting activity in patients with PVNS/TGCT, providing proof of concept for targeting CSF1R in this disease. The authors concluded that the benefits of alleviating morbidity in patients with localized PVNS/TGCT must be balanced against the potential toxicity of chronic drug therapy.

Published
2012

38. Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial

Author

Nishida, T., primary, Casali, P.G., additional, Reichardt, P., additional, Kang, Y.-K., additional, Blay, J.-Y., additional, Joensuu, H., additional, Maki, R.G., additional, Rutkowski, P., additional, Hohenberger, P., additional, Gelderblom, H., additional, Leahy, M.G., additional, von Mehren, M., additional, Schoffski, P., additional, Blackstein, M.E., additional, Cesne, A.L., additional, Badalamenti, G., additional, Xu, J.-M., additional, Laurent, D., additional, Kuss, I., additional, and Demetri, G.D., additional

Published
2012
Full Text
View/download PDF

43. C01* - Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

Author

Casali, P.G., Reichardt, P., Kang, Y., Blay, J., Joensuu, H., Maki, R.G., Rutkowski, P., Hohenberger, P., Gelderblom, H., Leahy, M.G., von Mehren, M., Schoffski, P., Blackstein, M.E., Le Cesne, A., Badalamenti, G., Xu, J., Nishida, T., Laurent, D., Kuss, I., and Demetri, G.D.

Published
2015
Full Text
View/download PDF

47. Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study

Author

Garcia-Carbonero, R., primary, Supko, J.G., additional, Maki, R.G., additional, Manola, J., additional, Ryan, D.P., additional, Harmon, D., additional, Puchalski, T.A., additional, Goss, G., additional, Seiden, M.V., additional, Waxman, A., additional, Quigley, M.T., additional, Lopez, T., additional, Sancho, M.A., additional, Jimeno, J., additional, Guzman, C., additional, and Demetri, G.D., additional

Published
2005
Full Text
View/download PDF

48. Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy

Author

Garcia-Carbonero, R., primary, Supko, J.G., additional, Manola, J., additional, Seiden, M.V., additional, Harmon, D., additional, Ryan, D.P., additional, Quigley, M.T., additional, Merriam, P., additional, Canniff, J., additional, Goss, G., additional, Matulonis, U., additional, Maki, R.G., additional, Lopez, T., additional, Puchalski, T.A., additional, Sancho, M.A., additional, Gomez, J., additional, Guzman, C., additional, Jimeno, J., additional, and Demetri, G.D., additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results